Mölnlycke statement on market supply disruption affecting 2% CHG Wipes
November 16, 2026
Download the full statement (PDF)
To our GPO partners, distributors, health systems, and customers:
We are aware of a significant market disruption affecting the availability of 2% chlorhexidine gluconate cloths. We recognize the pressure this creates for hospitals and their supply levels. To ensure product availability for our customers, we are placing the following SKUs on allocation effective 11/16/2026. All orders above historical averages will be evaluated individually:
- 57541
- 57504
- 59911
- 59915
Our supply management approach
- Prioritize current customers. Our priority is hospitals and health systems that rely on Mölnlycke today.
- Use historical demand as the starting point. Orders from current customers will be managed against established purchasing patterns and expected expansion. We will monitor material changes closely and coordinate with our distributor partners to limit avoidable disruption.
- Support planned conversions already underway. Organizations already engaged with Mölnlycke on a planned, long-term conversion will be considered within existing forecasts and implementation plans, subject to confirmed availability.
- Evaluate incremental requests carefully. Requests from new or temporarily displaced customers will be reviewed based on product availability, requested volume, timing, clinical fit, and the ability to support implementation without putting existing customers at risk.
- Avoid commitments we cannot reliably fulfill. The current market gap is substantially larger than normal safety-stock levels, and our replenishment lead times are 3-4 months on most product codes. For that reason, availability may vary by product, quantity, location, and delivery date.
You can expect transparent discussions regarding realistic quantities, timing, and product options, as well as close coordination with our distributors, GPO partners, and health-system supply chain teams. Daily assessment of demand, inventory, and production signals will continue through the duration of this disruption. We also encourage our customers to collaborate closely with their distributors to ensure they are receiving the appropriate product quantities allocated.
For further support, please work with your Mölnlycke representative. To accelerate review of your product need, please provide your contact with the following information: the affected facility/IDN, current product utilization, monthly quantity required, requested start date, expected duration, and preferred distributor.
We understand that supply reliability is essential to patient care. Our approach is intended to be fair and transparent, protecting current customers while offering as much help as our operations allow. We appreciate your partnership as we navigate this major disruption together.
Sincerely,
Chris Barys
Marketing Manager - Antiseptics
Latest news
-
New leaders appointed for Mölnlycke Health Care
Gothenburg, Sweden. 3 November 2026. Mölnlycke® announces the appointment of Anders Andersson as Chief Executive Officer (CEO) of Mölnlycke Health Care and Fredrik Wallefors as President of Surgical, effective 1 January 2027.
-
Mölnlycke and AROA partner to expand access to Endoform in the US
Mölnlycke Health Care has entered an exclusive agreement with AROATM to co-promote EndoformTM in the United States in post-acute settings, effective 16 October 2026.
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
Atlanta, Georgia. 13 October 2026. No two pairs of hands are the same, yet surgical glove sizing has changed little over time. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, is launching MyFit™ by Biogel®, a more inclusive range of surgical glove fit options designed to better reflect the diversity of clinicians’ hand anatomy and help more healthcare professionals find a glove that supports comfort, safety and performance – all critical in the operating room.
-
Mölnlycke launches Biogel® Radiation Protection® gloves to tackle low adoption of hand protection in radiation-guided surgical procedures
Clinicians’ hands can receive up to 1,000 times more radiation than other parts of the body during image-guided procedures1; yet, radiation-attenuating gloves are used in only 10% of applicable cases2, putting healthcare professionals at risk of the damaging effects of radiation.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Mölnlycke Recognized with Cardinal Health 2026 Rising Star Award
Mölnlycke Health Care has been honored with the Cardinal Health 2026 Rising Star Award, recognizing outstanding performance as a new member of the Cardinal Health Performance Plus Program.The award was presented during Cardinal Health's National Sales Meeting, held the week of August 9th, and reflects the strength of the partnership between the two organizations across Advanced Wound Care, Patient Positioning, and Antiseptics.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. July 7, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.